Breadcrumb

James W. Hodge, Ph.D., MBA

James W. Hodge, Ph.D., M.B.A.

  • Center for Cancer Research
  • National Cancer Institute
Center for Immuno-Oncology

RESEARCH SUMMARY

Dr. Hodge is the Head of the Immunotherapeutics Section. This group investigates how combination immunotherapies and non-immune–based therapies affect tumor cells and specific components of the immune system. These studies form the rationale for novel immune- and non-immune-based combination clinical trials.

Dr. Hodge pioneered the development of vaccines and vaccine strategies for cancer immunotherapy including a) recombinant vectors to deliver tumor antigens, b) the use of costimulation to enhance antitumor T-cell responses, c) the combined use of vaccines with radiation, chemotherapy, and targeted small-molecule therapeutics. These concepts and therapeutics have been translated into many randomized multi-center trials at numerous Cancer Centers.

Areas of Expertise

Cancer Vaccines
Radiation
Chemotherapy
Combination Therapies
Cytotoxic T-cells (CTL)

Publications

Selected Key Publications

Exploiting docetaxel-induced tumor cell necrosis with tumor targeted delivery of IL-12

Franks SE, Santiago-Sanchez GS, Fabian KP, Solocinski K, Chariou PL, Hamilton DH, Kowalczyk JT, Padget MR, Gameiro SR, Schlom J, Hodge JW.
Cancer Immunol Immunother. 72(8): 2783-2797, 2023.
Full-Text Article
[ Journal Article ]

Exploiting the immunogenic potential of standard of care radiation or cisplatin therapy in preclinical models of HPV-associated malignancies

Kowalczyk JT, Fabian KP, Padget MR, Lopez DC, Hoke AT, Allen CT, Hermsen M, London NR Jr, Hodge JW.
J Immunother Cancer. 10(12): e005752, 2022.
Full-Text Article
[ Journal Article ]

Dying of stress: chemotherapy, radiotherapy, and small-molecule inhibitors in immunogenic cell death and immunogenic modulation

Fabian KP, Kowalczyk JT, Reynolds ST, Hodge JW.
Cells. 11(23): 3826, 2022.
Full-Text Article
[ Journal Article ]

Immune targeting of three independent suppressive pathways (TIGIT, PD-L1, TGFβ) provides significant antitumor efficacy in immune checkpoint resistant models

Franks SE, Fabian KP, Santiago-Sánchez G, Wolfson B, Hodge JW.
Oncoimmunology. 11(1): 2124666, 2022.
Full-Text Article
[ Journal Article ]

Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing

Wolfson B, Padget MR, Schlom J, Hodge JW.
J Immunother Cancer. 9(7): e002258, 2021.
Full-Text Article
[ Journal Article ]

Job Vacancies

We have no open positions in our group at this time, please check back later.

To see all available positions at CCR, take a look at our Careers page. You can also subscribe to receive CCR's latest job and training opportunities in your inbox.

Team

Cailyn Lee
Post-baccalaureate Fellow
Cailyn Lee
Jonelle K. Lee
Postdoctoral Fellow (CRTA)
Jonelle K. Lee, Ph.D.
Michelle Padget
Biologist
Michelle Padget
Francesca Rosato
Postdoctoral Fellow (Visiting Fellow)
Francesca Rosato, Ph.D.
Ginette Santiago-Sanchez
Postdoctoral Fellow (CRTA)
Ginette Santiago Sanchez, Ph.D.

News

Learn more about CCR research advances, new discoveries and more
on our news section.